News | November 03, 2021
Venus Remedies H1 net profit rises 315%
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The company reports revenue growth of 26% and PAT growth of 21% YoY
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
PAT rises to Rs 195.76 crore
India business contributes to a stellar performance
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Subscribe To Our Newsletter & Stay Updated
